Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Edoxaban versus vitamin K antagonist after TAVI in patients with atrial fibrillation
NL-OMON50179Phase 3Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of edoxaban in Atrial fibrillation (AFib) and aortic stenosis (AS) (2 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Net adverse clinical events (TIMI-based), Net adverse clinical events (BARC-based) and 24 more. Started Oct 2017; status: active, not recruiting.
02
Drugs
edoxaban
03
Conditions
Atrial fibrillation (AFib)aortic stenosis (AS)
Beyond the preview
Go deeper on NL-OMON50179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50179.